These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37167163)

  • 1. [Impact of vaccination with pneumococcal vaccines on recurrent pneumonia in patients with chronic obstructive pulmonary disease].
    Ignatova GL; Antonov VN
    Ter Arkh; 2022 Dec; 94(11):1257-1261. PubMed ID: 37167163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
    Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
    Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.
    Walters JA; Tang JN; Poole P; Wood-Baker R
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD001390. PubMed ID: 28116747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of compliance dynamics in patients with chronic obstructive pulmonary disease on the background of vaccination against pneumococcal infection.
    Jgnatova GL; Antonov VN
    Ter Arkh; 2018 Apr; 90(3):47-52. PubMed ID: 30701856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study.
    Ignatova GL; Avdeev SN; Antonov VN
    Sci Rep; 2021 Aug; 11(1):15948. PubMed ID: 34354113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of the impact of vaccination of pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with diabetes].
    Ignatova GL; Blinova EV; Antonov VN; Grebneva IV
    Ter Arkh; 2019 Nov; 91(11):49-54. PubMed ID: 32598610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparison of exacerbation and pneumonia before and after conjugated pneumococcal vaccination in patients with chronic obstructive pulmonary disease, and the effect of inhaled corticosteroid use on results.
    Vayısoğlu Şahin G; Karadeniz G; Polat G; Yalnız E; Ayrancı A; Demirci Üçsular F; Güçsav MO
    Tuberk Toraks; 2022 Jun; 70(2):149-156. PubMed ID: 35785879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of the effectiveness and long-term results of formation of adaptive immunity in the use of various medications and vaccination schemes against pneumococcal infection in patients with chronic obstructive pulmonary disease].
    Protasov AD; Zhestkov AV; Kostinov MP; Shteiner ML; Tezikov YV; Lipatov IS; Yastrebova NE; Kostinova AM; Ryzhov AA; Polishchuk VB
    Ter Arkh; 2017; 89(12. Vyp. 2):165-174. PubMed ID: 29488477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
    Sings HL
    Vaccine; 2017 Sep; 35(40):5406-5417. PubMed ID: 28602602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Choice of optimal vaccination tactics against pneumococcal infection from immunological and clinical standpoints in patients with chronic obstructive pulmonary disease].
    Protasov AD; Kostinov MP; Zhestkov AV; Shteiner ML; Magarshak OO; Kostinova TA; Ryzhov AA; Pakhomov DV; Blagovidov DA; Panina MI
    Ter Arkh; 2016; 88(5):62-69. PubMed ID: 27239929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of the effectiveness of joint or sequential vaccination with pneumococcal and influenza vaccines in patients with chronic obstructive pulmonary disease].
    Ignatova GL; Antonov VN; Blinova EV
    Ter Arkh; 2019 Aug; 91(8):12-17. PubMed ID: 32598748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of vaccine prophylaxis concentrated pneumococcal vaccine in patients with chronic obstructive lung disease and chronic heart failure.
    Ignatova GL; Antonov VN
    Ter Arkh; 2018 Aug; 90(8):53-62. PubMed ID: 30701949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease.
    Kopp A; Mangin O; Gantzer L; Lekens B; Simoneau G; Ravelomanantsoa M; Evans J; Bergmann JF; Sellier P
    Hum Vaccin Immunother; 2021 Jan; 17(1):162-169. PubMed ID: 32429734
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
    Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia.
    van Werkhoven CH; Huijts SM
    Clin Chest Med; 2018 Dec; 39(4):733-752. PubMed ID: 30390745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
    Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
    Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
    Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
    Dunne EM; Cilloniz C; von Mollendorf C; Lewnard J; Grant LR; Slack MPE; Jodar L; Theilacker C; Gessner BD
    Arch Bronconeumol; 2023 Mar; 59(3):157-164. PubMed ID: 36681604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
    Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.